FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy

Omeros Corporation announced that the FDA has given a special “rare pediatric disease” designation to its drug zaltenibart (OMS906) for treating complement 3 glomerulopathy (C3G), a very rare kidney disease that mainly affects children and young adults. This disease has no approved treatments and can lead to severe kidney failure within 10 years. Zaltenibart works by stopping a process in the body that contributes to the disease, and Omeros plans to start the final stage of testing the drug next year.